Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 7/20 | 0.91 |
| ▸ | PGR | P06401 | 5/20 | 0.91 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.91 |
| ▸ | MAPT | P10636 | 2/20 | 0.91 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.91 |
| ▸ | DRD2 | P14416 | 1/20 | 0.91 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.91 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.81 |
| ▸ | USP2 | O75604 | 5/20 | 0.81 |
| ▸ | LMNA | P02545 | 3/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.81 |
| ▸ | MLNR | O43193 | 1/20 | 0.81 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.81 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.81 |
| ▸ | PPARG | P37231 | 1/20 | 0.81 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.81 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.75 |
| ▸ | CNR1 | P21554 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30491082 | 1.00 | NR3C1 (0.91) | NR3C1PGRNR1I2MAPTADORA3 | |
| SCHEMBL25370010 | 1.00 | NR3C1 (0.91) | NR3C1PGRNR1I2MAPTADORA3 | |
| Betamethasone Dipropionate SCHEMBL13028946 | 0.95 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Betamethasone Dipropionate SCHEMBL11429865 | 0.95 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Betamethasone Dipropionate SCHEMBL4566 | 0.95 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Betamethasone Dipropionate SCHEMBL20097870 | 0.95 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Betamethasone Dipropionate SCHEMBL10013893 | 0.95 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Betamethasone Dipropionate SCHEMBL9768468 | 0.95 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Dexamethasone Dipropionate SCHEMBL43107 | 0.95 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 | |
| Betamethasone Dipropionate SCHEMBL14339597 | 0.95 | NR3C1 (1.00) | NR3C1PGRNR1I2MAPTADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12440499-B2 | Topical composition | MC2 Therapeutics Limited (GB) | 2025-10-14 | — | — | US | disclosed |
| US-20230277452-A1 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING NASAL, OTIC AND OTHER TISSUE INFECTION AND/OR INFLAMMATION | OTICARA, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| CN-116600785-A | Compositions, devices and methods for treating infection and/or inflammation of the nose, ear and other tissues | 奥蒂卡拉股份有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-113499343-B | Topical compositions | MC2疗法有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-20230226077-A1 | TOPICAL COMPOSITION | MC2 Therapeutics Limited (GB) | 2023-07-20 | — | — | US | disclosed |
| US-11696919-B2 | Topical composition | MC2 Therapeutics Limited (GB) | 2023-07-11 | — | — | US | disclosed |
| EP-4203958-A1 | COMPOSITIONS DEVICES AND METHODS FOR TREATING NASAL, OTIC AND OTHER TISSUE INFECTION AND/OR INFLAMMATION | Oticara, Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| WO-2022047042-A1 | COMPOSITIONS DEVICES AND METHODS FOR TREATING NASAL, OTIC AND OTHER TISSUE INFECTION AND/OR INFLAMMATION | OTICARA, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| US-9655907-B2 | Topical formulations comprising a steroid | DR. REDDY'S LABORATORIES LTD. (IN) | 2017-05-23 | — | — | US | disclosed |
| US-20160361325-A1 | TOPICAL FORMULATIONS COMPRISING A STEROID | PRIMUS PHARMACEUTICALS, INC. | 2016-12-15 | — | — | US | disclosed |
| US-8858618-B2 | Stent | TERUMO KABUSHIKI KAISHA (JP) | 2014-10-14 | — | — | US | disclosed |
| US-20120197385-A1 | STENT | TERUMO KABUSHIKI KAISHA (JP) | 2012-08-02 | — | — | US | disclosed |
| EP-0721956-B1 | 21-SUBSTITUTED STEROID COMPOUND | NISSIN FOOD PRODUCTS LTD (JP) | 2000-08-02 | — | — | EP | disclosed |
| EP-0721956-A1 | 21-SUBSTITUTED STEROID COMPOUND | NISSIN SHOKUHIN KABUSHIKI KAISHA (JP) | 1996-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361325-A1 | TOPICAL FORMULATIONS COMPRISING A STEROID | NR5A1, CYP17A1, TSLP | NR3C1 11/4885PGR 233/4885NR1I2 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.